Latest From Illumina Inc.
Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.
Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.
Drug Discovery Tools
- Nanotechnology, Chips, etc.
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Illumina Inc.
- Senior Management
Francis deSouza, Pres. & CEO
Sam Samad, CFO
Mark Van Oene, SVP, Chief Commercial Officer
Garrett Hampton, PhD, EVP, Clinical Genomics
Omead Ostadan, EVP, Products & Ops
Joydeep Goswami, SVP, Corp Dev. & Strategic Planning
Mostafa Ronaghi, PhD, SVP, CTO
- Contact Info
Phone: (858) 202-4500
5200 Illumina Way
San Diego, CA 92122
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.